Table 1.
Demographics and clinical profile of the three participant groups
| Group | |||
|---|---|---|---|
| Control (n = 43) |
Migraine (n = 56) |
TTH (n = 49) |
|
| Age | 36.2 ± 7.7 | 37.5 ± 7.6 | 39.0 ± 12.0 |
| Gender | 28F/15M | 37F/19M | 26F/23M |
| Episodic/chronic | – | 31/25 | 25/24 |
| Headache frequency (d/mo) | – | 13.8 ± 10.5 | 14.0 ± 10.6 |
| Disease duration (mo) | – | 194.6 ± 116.7 | 156.1 ± 144.5 |
| Headache intensity (0–10) a | – | 5.9 ± 2.1 | 3.5 ± 1.3 |
| MIDAS (0–270) a | – | 26.1 ± 35.8 | 8.9 ± 16.8 |
| BDI (0–63) b,c | 4.2±4.8 | 8.7± 5.7 | 7.3 ± 5.0 |
| Analgesics use profile | |||
| Frequency (d/mo) a | – | 4.4 ± 2.5 | 1.6 ± 2.5 |
| Types of analgesics (% of patients) | |||
| Simple analgesics | 16.1% | 12.2% | |
| Compound analgesics | 5.4% | 4.0% | |
| NSAIDs | 8.9% | 6.1% | |
| Ergots | 5.4% | 0% | |
| Triptans | 5.4% | 0% | |
BDI Beck Depression Inventory, d days, MIDAS migraine disability assessment, mo month, NSAIDs Nonsteroidal anti-inflammatory drugs, TTH tension-type headache
ap < 0.05 for migraine vs. TTH
bp < 0.05 for migraine vs. control
cp < 0.05 for TTH vs. control